Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Michael P. Chu, MD, Andrew Belch, MD, Lixia Pei, PhD, Xue (Loya) Yang, PhD, Tadeusz Robak, MD PhD, Brendan Rooney, PhD, Andrew Cakana, MD, Helgi van de Velde, MD PhD, Michael B Sawyer, MD

Blood (2015) 126 (23): 1477.

https://doi.org/10.1182/blood.V126.23.1477.1477

Published: 2015

Journal Articles

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo

Blood (2014) 124 (16): 2498–2506.

https://doi.org/10.1182/blood-2014-04-568329

Published: 2014

Includes: Supplemental data

Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1986.

https://doi.org/10.1182/blood.V122.21.1986.1986

Published: 2013

Journal Articles

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Dina Gifkins, PhD, Megan McAuliffe, ScD, Amy Matcho, BS, Jane Porter, MS, Scott Chavers, PhD, Maria Ponsillo, MD, Jay King, MD, Avinash Desai, MD, Andrew Cakana, MD, Dixie-Lee Esseltine, MD

Blood (2011) 118 (21): 3972.

https://doi.org/10.1182/blood.V118.21.3972.3972

Published: 2011

Journal Articles

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Robert A. Vescio, Kevin Liu, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, Raymond L. Comenzo

Blood (2011) 118 (4): 865–873.

https://doi.org/10.1182/blood-2011-02-334227

Published: 2011

Includes: Supplemental data

Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH

Blood (2010) 116 (21): 2563.

https://doi.org/10.1182/blood.V116.21.2563.2563

Published: 2010

Journal Articles

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Dixie-Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel

Blood (2010) 116 (19): 3743–3750.

https://doi.org/10.1182/blood-2010-03-275800

Published: 2010

Includes: Supplemental data

Journal Articles

Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.

Heinz Ludwig, Luisa Viterbo, Richard Greil, Tamas Masszi, Ivan Spicka, Ofer Shpilberg, Roman Hajek, Anna Dmoszynska, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean-Luc Harousseau

Blood (2009) 114 (22): 2312.

https://doi.org/10.1182/blood.V114.22.2312.2312

Published: 2009

Journal Articles

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

Si-Tien Wang, Hui Huang, Hongliang Shi, Mei Sheng Duh, Kristina Chen, Eva Chang, Caroline Korves, Ravinder Dhawan, Andrew Cakana, Helgi van de Velde, Dixie-Lee Esseltine, Louis Garrison

Blood (2009) 114 (22): 1379.

https://doi.org/10.1182/blood.V114.22.1379.1379

Published: 2009

Journal Articles

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Donna E. Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean-Paul Fermand, Robert A. Vescio, Xiangyang Liu, Yusri A. Elsayed, Andrew Cakana, Raymond L. Comenzo, for the VELCADE CAN2007 Study Group

Blood (2009) 114 (8): 1489–1497.

https://doi.org/10.1182/blood-2009-02-203398

Published: 2009

Includes: Supplemental data

Journal Articles

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Blood (2008) 112 (11): 650.

https://doi.org/10.1182/blood.V112.11.650.650

Published: 2008

Journal Articles

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul Richardson, Rudolf Schlag, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Rik Schots, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F San Miguel

Blood (2008) 112 (11): 2778.

https://doi.org/10.1182/blood.V112.11.2778.2778

Published: 2008

Journal Articles

Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results

Miklos Udvardy, Attila Kiss, Bela Telek, Robert Szasz, Peter Batar, Gyula Remenyi, Andrew Cakana, Laszlo Rejto

Blood (2008) 112 (11): 4000.

https://doi.org/10.1182/blood.V112.11.4000.4000

Published: 2008

Journal Articles

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Meletios A Dimopoulos, Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin H Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A Alexeeva, Rik Schots, Tamas Masszi, Maria-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesus F San Miguel

Blood (2008) 112 (11): 1727.

https://doi.org/10.1182/blood.V112.11.1727.1727

Published: 2008

Journal Articles

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Maria Teresa Petrucci, Victor A Rossiev, Jian Hou, Tadeusz Robak, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F. San Miguel

Blood (2008) 112 (11): 1741.

https://doi.org/10.1182/blood.V112.11.1741.1741

Published: 2008

NARROW

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial.

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone

Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only